Evonik is set to expand its 3D-printable biomaterials portfolio for medical technology with the introduction of new VESTAKEEP iC4800 3DF osteoconductive PEEK filament.

The new PEEK filament for 3D-printable implants is a biomaterial from Evonik’s VESTAKEEP Fusion product line, which was launched in 2020.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

VESTAKEEP iC4800 3DF improves fusion between bone and implants.

The PEEK filament, with a diameter of 1.75mm, can be processed in common extrusion-based 3D printing technologies, such as fused filament fabrication (FFF).

With good biocompatibility and biostability, the polymer features improved osteoconductive properties.

The osteoconductivity of VESTAKEEP iC4800 3DF was achieved through the use of biphasic calcium phosphate (BCP), a functional special additive.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The additive accelerates patient recovery by allowing bone cells to adhere to implants more quickly.

VESTAKEEP iC4800 3DF has been specifically designed to ensure that the functional additives are placed directly on the surface of the 3D printed implant, eliminating additional post-processing steps.

Evonik medical systems head Marc Knebel said: “No other application field showcases more the classic advantages of 3D printing, such as individualisation or design freedom, than medical technology.

“Since the product launch of the first PEEK filament a good three years ago, we have been expanding the possibilities of modern medical technology in the individual treatment of patients using additive manufacturing by constantly developing new innovative biomaterials.”

In 2019, the company signed a long-term agreement with BellaSeno, a German additive manufacturing start-up, for the development of an innovative breast implant technology.

Evonik’s portfolio also includes VESTAKEEP Care M40 3DF, VESTAKEEP i4 3DF and the RESOMER line of bioresorbable filaments, powders and granules for implantable medical devices.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact